The subscription period in IRLAB’s rights issue commences today
Today, 11 June 2026, the subscription period commences in IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) issue of ordinary shares of series A with preferential rights for existing shareholders up to approximately SEK 68 million (the “Rights Issue”), which was resolved by the Board of Directors on 5 May 2026 and was approved by the Extraordinary General Meeting on 5 June 2026. The subscription period in the Rights Issue will run until 25 June 2026. However, please note that certain banks and nominees may apply an earlier deadline for subscription. Shareholders are therefore advised to check with their bank or nominee regarding any earlier deadline that may apply.
Read More >
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat and reduce risk of falling and falls in Parkinson’s disease.
Kristina Torfgård, CEO and Gustaf Albèrt, CFO present at Aktiesdagarna
CEO Kristina Torfgård and CFO Gustaf Albèrt present IRLAB’s world-leading portfolio: five drug candidates with the potential to revolutionize the treatment of Parkinson’s disease (presentation in Swedish). Published June 9, 2026.
Read More >